Business Club March 3 hearing Sanpu Pharmaceutical (600869) annual report shows that in 2010 the company achieved operating income of 9.46 billion yuan, an increase of 38.6%; net profit attributable to shareholders of listed companies 022 million yuan, an increase of 47.65%; Earnings of 0.71 yuan.
In 2011, the company's main business objectives were: operating income of 1,250,734 million yuan, net profit of 402.99 million yuan, and employees' per capita annual income and benefits have been greatly improved. The company will do its best to promote the non-public issuance of fundraising work, and look for target companies that are highly related to the main business or technological breakthroughs, and try to use the opportunity of restructuring to conduct industry consolidation and mergers and acquisitions.
In addition, the company plans to invest 20 million yuan to participate in the establishment of Jiangsu Sanpu Prophet Biological Technology Co., Ltd. (tentative name), holding 60% of the shares; plans to invest 30 million yuan Far East Cable Trading Co., Ltd. (tentative name).
The company plans to set up Jiangsu Sanpu Prophet Biotechnology Co., Ltd. to strengthen the company's pharmaceutical industry, expand its business scope, extend its industrial chain, and develop the test reagent industry for organ and stem cell transplantation rejection reaction; it is planned to establish Far East Cable Trading Co., Ltd. for implementation. The company's future development strategy, seize the business opportunities of cable e-commerce, integrate relevant resources, and promote the transformation of cable industry economic growth mode.
Since November last year, the company’s stock price has increased significantly. On the most recent trading day, the closing price of the company's shares was 35.9 yuan, compared with only 18.86 yuan at the beginning of November 2010. The market is optimistic that the company may be affected by the company's previously disclosed private placement program. According to the announcement of the company on December 31, 2010, the company plans to issue no more than 72 million shares non-publicly at a price of no less than 21.69 yuan/share, with no more than 156.168 million yuan raised, mainly for special cables for new energy, Smart grid ultra-high voltage cable, high-strength energy-saving environmentally friendly special wire and other projects. (Author: Gu Xin)
In 2011, the company's main business objectives were: operating income of 1,250,734 million yuan, net profit of 402.99 million yuan, and employees' per capita annual income and benefits have been greatly improved. The company will do its best to promote the non-public issuance of fundraising work, and look for target companies that are highly related to the main business or technological breakthroughs, and try to use the opportunity of restructuring to conduct industry consolidation and mergers and acquisitions.
In addition, the company plans to invest 20 million yuan to participate in the establishment of Jiangsu Sanpu Prophet Biological Technology Co., Ltd. (tentative name), holding 60% of the shares; plans to invest 30 million yuan Far East Cable Trading Co., Ltd. (tentative name).
The company plans to set up Jiangsu Sanpu Prophet Biotechnology Co., Ltd. to strengthen the company's pharmaceutical industry, expand its business scope, extend its industrial chain, and develop the test reagent industry for organ and stem cell transplantation rejection reaction; it is planned to establish Far East Cable Trading Co., Ltd. for implementation. The company's future development strategy, seize the business opportunities of cable e-commerce, integrate relevant resources, and promote the transformation of cable industry economic growth mode.
Since November last year, the company’s stock price has increased significantly. On the most recent trading day, the closing price of the company's shares was 35.9 yuan, compared with only 18.86 yuan at the beginning of November 2010. The market is optimistic that the company may be affected by the company's previously disclosed private placement program. According to the announcement of the company on December 31, 2010, the company plans to issue no more than 72 million shares non-publicly at a price of no less than 21.69 yuan/share, with no more than 156.168 million yuan raised, mainly for special cables for new energy, Smart grid ultra-high voltage cable, high-strength energy-saving environmentally friendly special wire and other projects. (Author: Gu Xin)
Soft Capsule,Milk Thistle Capsule,Dietary Supplement Capsule,Cranberry Extract Vegetarian Capsule
Weihai Baihe Biology Technological Co., Ltd. , https://www.biohighnutraceutical.com